On November 28, 2021 Subtle Medical, a leading healthcare technology company, and Bayer, a leading life science company with extensive expertise from diagnosis to care, reported a collaboration to explore opportunities to utilize AI (artificial intelligence) to aid in image acquisition in radiology (Press release, Bayer, NOV 28, 2021, View Source [SID1234596168]). The companies will investigate the potential of Subtle Medical’s state-of-the-art AI algorithm, SubtleGAD, for use in contrast-enhanced MRI exams to enhance image quality and will explore potential new areas for contrast media use.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Bayer, we are constantly striving to advance medical knowledge and provide the best possible therapeutic and diagnostic options for physicians and patients," said Prof. Dr. Olaf Weber, Head of Radiology Research and Development at Bayer. "We are pleased to collaborate with Subtle Medical to harness the power of AI, with the ultimate goal of providing physicians with the means for optimal diagnosis for their patients."

Subtle Medical’s AI technologies acquire and improve high quality images from both accelerated and low dose scans.

MRI exams enable physicians to obtain detailed images of the body and help them answer critical medical questions in the diagnosis and monitoring of disease. In light of an aging population, the need for medical imaging to facilitate diagnosis, treatment decisions and therapy planning has grown. Artificial intelligence is a promising tool to support radiologists in their task to provide accurate and timely diagnosis to their patients, in addition to offering opportunities to speed up imaging exam times and reduce dose. In particular, Subtle Medical’s suite of deep learning technologies aid in higher quality image acquisition from both accelerated and low dose scans. Both companies are looking forward to joining forces to drive innovation in medical imaging.

"We are proud to collaborate with Bayer to combine our expertise and drive innovative solutions in light of the ever increasing demands of medical imaging," said Dr Ajit Shankaranarayanan, Chief Product Officer at Subtle Medical. "At Subtle Medical, we are committed to continued innovation and the development of AI tools that create a meaningful impact for both radiologists and patients."

Subtle Medical’s clinically validated AI-powered software solutions increase the efficiency of image capture by improving the quality of accelerated and low dose imaging. Subtle’s solutions are compatible with all scanner brands, models and field strengths so institutions can see the benefit across their entire scanner fleet. Meet with Subtle Medical at RSNA 2021.

"Bayer is a key partner due to their clinical expertise and proven track record in medical imaging. Such collaborations across the industry will be crucial to unlock the power of AI, ultimately benefiting patients, improving imaging capabilities and patient diagnosis worldwide," said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

On November 28, 2021 GE Healthcare reported that unveiled around 60 innovative technology solutions spanning the healthcare spectrum including patient screening, diagnostics, therapy planning, guidance, and monitoring (Press release, GE Healthcare, NOV 28, 2021, View Source [SID1234596167]). Amidst a global pandemic and mounting pressure on the industry, the company accelerated innovations underpinned by artificial intelligence (AI) and digital solutions to help transform healthcare delivery, making it easier and more efficient for clinicians and health systems, and more personalized and precise for patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pandemic exposed the fragility of the global healthcare system, creating an urgent need for technology and solutions that help clinicians manage seriously ill COVID-19 patients, advanced diseases – such as cancer and heart disease – a backlog in non-urgent care, and an ageing population, while battling burnout and workforce shortages.

With these circumstances in mind, GE Healthcare is proud to introduce technologies and solutions at #RSNA21 that help healthcare systems:

Increase efficiency and productivity;
Reduce clinician burnout;
Empower clinicians with AI and analytics when, where and how they need it;
Create a more resilient and sustainable healthcare industry; and
Increase access to care.
"Our goal is to make healthcare more human by breaking down barriers so clinicians can work at the top of their game, healthcare systems can operate more efficiently, and patients can get the best and most personalized care possible," said Kieran Murphy, president & CEO, GE Healthcare. "Healthcare is at a turning point and at GE Healthcare we are using our clinical expertise and know-how to deliver innovative technologies and solutions that help solve healthcare’s most pressing problems, advance precision health and improve patient lives."

Transforming healthcare through imaging technologies and digital offerings

Over the last year and a half, the industry has embraced technological innovation. What was once considered "futuristic" is now fundamental. In an environment where clinical expertise, regulatory know-how and speed matter, GE Healthcare rose to the challenge. Working alongside clinicians and care teams to understand the most pressing needs of radiologists and hospital administrators, the company innovated new solutions, leveraging its healthcare-specific intelligence platform, Edison, to help providers achieve greater efficiency, reduce errors, increase speed to appropriate treatments, and increase access to care.

To this end, GE Healthcare developed the following new AI-powered, automated and data-driven solutions to help encourage greater diagnostic confidence, ease the burden of care and improve workflow for healthcare systems around the world:

SIGNA Heroi is named for our heroes on the frontlines, who continue to care for seriously ill patients as well as a backlog in non-urgent care – all the while battling burnout and workforce shortages. The new 3.0T MRI system offers new workflows and AIR Recon DL enhancements designed to help our heroes on the frontlines address some of today’s most pressing healthcare needs: enhanced productivity, patient comfort, and sustainabilityii.
SIGNA Artist Evoiii enables healthcare systems to modernize their legacy 1.5T narrow 60 cm bore MR systems to 1.5T, 70 cm bore systems, accommodating more patients of different shapes and sizes. Furthermore, the company’s patented flexible AIR Coils design and AIR Recon DL image reconstruction help provide clearer, sharper and more detailed images faster – enabling shorter patient setup times and reducing table time.
Revolution Apex platformiv provides exceptional image quality and low dose scanning for routine and challenging cases in many care areas with optimized clinical capabilities, built-in scalability and upgradability options.
Allia Platform is designed to enhance user experience, improve workflow efficiency and increase the adoption of advanced image guidance in daily practice – all important factors in today’s constrained healthcare environment. In addition to personalizing the Interventional or hybrid operating room with just one click of the user interface, leveraging the Edison platform, the system also harnesses the power of AI with AutoRightv – an advanced AI-based interventional image chain – and Liver ASSIST Virtual Parenchymavi,vii– a 3D visualization software solution designed to provide AI-based virtual parenchymography to help clinicians simulate injections dynamically and perform liver embolization procedures with confidence.
AMX Navigate represents GE Healthcare’s latest in portable x-ray technology with a new Zero Click Exam workflow solution and power-assisted Free Motion telescoping column to reduce lift force by an estimated 70 percentviii, helping to decrease X-ray technologist strain . The rugged reliability of the AMX Navigate helps ensure it is ready to perform at the bedside of the patient.
Critical Care Suite 2.0 offers a collection of AI algorithms embedded on a mobile x-ray device for case prioritization, automated measurements, and quality control. For the past year, the suite’s AI algorithm to help clinicians assess Endotracheal Tube (ETT) placements has helped clinicians care for an influx of critically ill COVID-19 patients who required ventilation under the FDA COVID-19 imaging guidance. Now, Critical Care Suite 2.0 has received full Food and Drug Administration (FDA) 510(k) clearance.
Vscan Air provides clinicians with quick insights at the point of care at a time when they need it most. This wireless and pocket-sized ultrasound device provides exceptionally clear image quality, whole-body scanning capabilities, and intuitive software – all in the palm of the clinician’s hand. A dual-probe enables whole-body scanning – with the flip of the wireless dual probe (for deep and shallow scanning) and a push of a button to capture images. Vscan Air offers a high-performance ultrasound machine in a lightweight, portable device designed to improve patient experience and access to ultrasound technology – involving patients by sharing real-time image sharing as simple as see, snap, send.
Enterprise Imaging in the Cloud delivers the power of technology in a smart, digital ecosystem giving radiologists easy and seamless access to GE Healthcare’s latest AI-based tools, data and intelligent technology for visualization, diagnostics and workflow as well as third party algorithms – from anywhere, anytimeix,x. The solution is cloud-based, enabling healthcare systems to manage upgrades instantly and digitally, with little to no new hardware or on-site IT team required.
Digital Expert Access is a real-time virtual collaboration solution that is integrated into imaging devices. With imaging experts in short supply and high demand and imaging moving beyond hospital campuses, Digital Expert Access allows sharing of expertise, best practices, and in-the-moment advice, as well as remote console control – all from a distance.
ulrichINJECT CT Motion uses automated syringeless technology to support workflow efficiencies. The injector, now approved with RIS/PACS integration, removes the need for manual syringe filling which may minimize examination preparation time and minimize contrast media waste.
A partner of choice creating and investing in new possibilities for the healthcare industry

As innovators, integrators and clinical experts, GE Healthcare is aligning its products and solutions across care pathways, such as oncology, to create end-to-end solutions.

The company is working with industry leaders, such as SOPHiA GENETICS, to deliver on the promise of integrated cancer care by bringing insights across multiple diagnostic modalities with the goal of better targeting and matching treatments to each patient’s cancer type, helping to ensure more effective and personalized treatment. Through the acquisition of Zionexa, the company is advancing precision diagnostics and impacting clinical care by commercializing innovative molecular imaging agents.

Furthermore, GE Healthcare offers deep industry expertise, an ability to merge clinical and data science and a breadth of solutions across pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, PET/MR, nuclear medicine, advanced digital solutions, and pharmaceutical partnerships – all to help clinicians enhance patient care from discovery to diagnosis to treatment.

Using input from clinical partners, GE Healthcare has designed technologies and digital solutions to keep up with the ever-changing challenges that exist in the imaging world. The Revolution Apex platform, for example, is designed with advanced technologies intended to:

Support one-beat cardiac imaging with motion management;
Update their service line from a 40 mm detector and 0.28 second rotation speed up to a 160 mm detector and 0.23 second per rotation speed (FDA 510(k) pending) xi,xii ; and
Reduce contrast dose up to 33% potentially.
"I’m a fan of the new Apex [platform] system and all the possibilities around it. For us, it’s a big win," said Johan de Mey, MD, PhD, Chair of Radiology at the Universitair Ziekenhuis, Brussels, Belgium. "In the past, we kept machines as long as possible, and we upgraded them with software. But if the hardware was obsolete, we removed it from the hospital. With the Apex, we have a platform with the latest technology and can easily upgrade as our clinical practice evolves."

Altogether, GE Healthcare is a partner of choice to thousands of healthcare providers, medical technology innovators, and digital start-ups around the world.

On November 26, 2021, Propanc Biopharma, Inc. (the "Company") reported that it entered into a securities purchase agreement (the "Purchase Agreement") with Sixth Street Lending, LLC ("Sixth Street"), pursuant to which Sixth Street purchased a convertible promissory note (the "Note") from the Company in the aggregate principal amount of $53,750, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Sixth Street (Filing, 8-K, Propanc, NOV 26, 2021, View Source [SID1234596327]). The transaction contemplated by the Purchase Agreement is expected to close on or about December 2, 2021. The Company intends to use the net proceeds ($50.000) from the Note for general working capital purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The maturity date of the Note is November 26, 2022 (the "Maturity Date"). The Note shall bear interest at a rate of 8% per annum, which interest may be paid by the Company to Sixth Street in shares of common stock, but shall not be payable until the Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment, as described below. Sixth Street has the option to convert all or any amount of the principal face amount of the Note, starting on May 20, 2022 and ending on the later of the Maturity Date and the date of payment of the Default Amount (as defined below) is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the Note shall be equal to the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 65% multiplied by the Market Price (as defined herein) (representing a discount rate of 35%). "Market Price" means the average of the lowest three (3) Trading Prices (as defined below) for the Common Stock during the ten (10) Trading Day period ending on the latest complete Trading Day prior to the Conversion Date. "Trading Price" means, for any security as of any date, the closing bid price on the OTCQB, OTCQX, Pink Sheets electronic quotation system or applicable trading market (the "OTC") as reported by a reliable reporting service designated by Sixth Street (i.e. Bloomberg) or, if the OTC is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets". Notwithstanding the foregoing, Sixth Street shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Sixth Street and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock.

The Note may be prepaid until 180 days from the issuance date. If the Note is prepaid within 60 days of the issuance date, then the prepayment premium shall be 110% of the face amount plus any accrued interest, if prepaid after 60 days from the issuance date, but less than 91 days from the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest, if prepaid after 90 days from the issuance date, but less than 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest, if prepaid after 120 days from the issuance date, but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest, and if prepaid after 150 days from the issuance date, but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest. So long as the Note is outstanding, the Company covenants not to, without prior written consent from Sixth Street, sell, lease or otherwise dispose of all or substantially all of its assets outside the ordinary course of business which would render the Company a "shell company" as such term is defined in Rule 144. Pursuant to the terms of the Purchase Agreement, the Company paid Sixth Street’s fees and expenses in the aggregate amount of $3,750.

Other than as described above, the Note contains certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Note. Additional events of default shall include, among others: (i) failure to reserve at least five times the number of shares issuable upon full conversion of the Note; (ii) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Company or any subsidiary of the Company; provided, that in the event such event is triggered without the Company’s consent, the Company shall have sixty (60) days after such event is triggered to discharge such event, (iii) the Company’s failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq Small Cap Market, the New York Stock Exchange, or the American Stock Exchange, (iv) The restatement of any financial statements filed by the Company with the SEC at any time after 180 days after the issuance date for any date or period until this note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have reasonably constituted a material adverse effect on the rights of Sixth Street with respect to this note or the Purchase Agreement, and (v) the Company’s failure to comply with its reporting requirements of the Securities and Exchange Act of 1934 (the "Exchange Act"), and/or the Company ceases to be subject to the reporting requirements of the Exchange Act.

In the event that the Company fails to deliver to Sixth Street shares of common stock issuable upon conversion of principal or interest under the Note within three business days of a notice of conversion by Sixth Street, the Company shall incur a penalty of $1,000 per day, provided, however, that such fee shall not be due if the failure to deliver the shares is a result of a third party such as the transfer agent.

Upon the occurrence and during the continuation of certain events of default, the Note will become immediately due and payable and the Company will pay Sixth Street, in full satisfaction of its obligations in the Note an amount equal to 150% of an amount equal to the then outstanding principal amount of the Note plus any interest accrued upon such event of default or prior events of default (the "Default Amount").

The Note was issued, and any shares to be issued pursuant to any conversion of the Note shall be issued, in a private placement in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

The foregoing description of the Note and the Purchase Agreement does not purport to be complete and is qualified in their entirety by reference to the full text of the Purchase Agreement and the Note, which are filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by referenc

On November 26, 2021Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that it was awarded of the 2021 Innovation Award in the "Life Sciences" category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021 (Press release, Theratechnologies, NOV 26, 2021, View Source [SID1234596239]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Every year, the ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) gala rewards Quebec-based companies for leadership in innovation in their respective field.

At the beginning of 2021, Theratechnologies received the United States Food and Drug Administration’s "Fast-track" designation for TH1902 as a single agent for the treatment of patients with advanced and recurrent solid tumors expressing the sortilin receptor and refractory to standard treatments. TH1902 is the lead peptide-drug conjugate derived from the SORT1+ Technology in oncology.

"It is quite rare to obtain the "fast-track" designation this early in the drug development process and this was achieved through spectacular preclinical data. We are very proud of this achievement and look forward to the future with great hope for patients," said Mr. Paul Lévesque, President and Chief Executive Officer of Theratechnologies.

About TH1902
TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This peptide-drug conjugate is the lead candidate stemming from Theratechnologies’ SORT1+ Technology in oncology.

The Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), contributes a total of 1.4 million dollars towards some of the research currently being conducted for the development of Theratechnologies’ targeted oncology platform.

On November 26, 2021 The two co-founders of the WuXi AppTech/WuXi Biologics CROs, Drs. Ge Li and Ning Zhao,reported that they have made a $20 million charitable gift to Memorial Sloan Kettering Cancer Center (MSK) in New York City for cancer research (Press release, WuXi AppTec, NOV 26, 2021, View Source [SID1234596161]). The Ge Li & Ning Zhao Family Foundation gave the money to MSK to support lung cancer research and develop new therapies. The money will be used to create three Ning Zhao & Ge Li endowed chairs at MSK and a research fund to underwrite basic, translational and clinical research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Specifically, The Ning Zhao & Ge Li Family Initiative for Lung Cancer Research and New Therapies will seek to create a deeper understanding of lung cancer biology, which can be used to develop new targeted therapies to overcome drug resistance and to prevent metastasis in lung cancer.

Lung cancer is responsible for 25% of all cancer deaths, the leading cause of cancer deaths among men and women in the US. Although lung cancer rates are dropping, more research and better treatments are needed.

In addition, the initiative will support critical new research projects led by research fellows and fund essential related work in the Department of Pathology.

Founded in 2000 as Wuxi PharmaTech, offering basic lab services to pharmaceutical companies, WuXi AppTech and WuXi Biologics have grown to have a worldwide reach, with facilities in many countries and a combined market capitalization of $90 billion.

The Ge Li & Ning Zhao Family Foundation is dedicated to advancing education, scientific research, and healthcare innovations to improve the well-being of humanity. The Family Foundation was created in 2020 through the generosity of Dr. Ge Li and Dr. Ning Zhao.

Ge Li, PhD, is Chairman of WuXi AppTec and WuXi Biologics. Ning Zhao, PhD, is a member of the board, Senior Vice President and Global Head of Human Resources at WuXi AppTec, and President of the Ge Li & Ning Zhao Family Foundation.

"We are deeply grateful for this gift, which will enable MSK to continue its leadership in the treatment of lung cancer and allow us to devote even more resources to researching the disease at every stage," said Craig B. Thompson, MD, President and CEO of MSK.

"Our team of lung cancer researchers and clinicians is so excited by the opportunity provided by this gift to accelerate the discovery and implementation of new lung cancer therapies," said Charles M. Rudin, MD, PhD, Chief of MSK’s Thoracic Oncology Service and Co-Director of the Fiona and Stanley Druckenmiller Center for Lung Cancer Research, which will house the new initiative. "The exceptional generosity of the Ge Li & Ning Zhao Family Foundation will make a significant impact on what our thoracic team is able to accomplish in the years to come."

"The specialists at MSK are among the most experienced in the treatment of lung cancer in the world," said David R. Jones, MD, Chief of the Thoracic Service in the Department of Surgery at MSK and Co-Director of the Druckenmiller Center for Lung Cancer Research. "We offer our patients the most compassionate care and advanced treatment, whether it be surgery, chemotherapy, targeted therapies, immunotherapy or radiation. This generous gift comes at a crucial time in the fight against lung cancer and will enable us to bring new treatment approaches to our patients faster."

"We are excited to contribute to the significant research being done at Memorial Sloan Kettering in the field of lung cancer," Dr. Li and Dr. Zhao shared. "Advancing cancer research is a cause we care deeply about, and it will be extremely gratifying to witness the doctors and researchers put this gift to good use. We look forward to seeing their advances and discoveries in the future."

MSK has pioneered advances in lung cancer and continues working to develop new and more durably effective treatment approaches. Its recent breakthroughs include novel targeted therapies, immunotherapies, robotic bronchoscopy and newer forms of precise radiation such as proton therapy.

As the world’s oldest and largest private cancer center, Memorial Sloan Kettering has devoted more than 135 years to high-level patient care, influential educational programs, and innovative research. MSK is home to more than 20,000 physicians, scientists, nurses, and staff.